rdf:type |
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0003250,
umls-concept:C0003873,
umls-concept:C0025677,
umls-concept:C0027540,
umls-concept:C0031809,
umls-concept:C0031928,
umls-concept:C0036043,
umls-concept:C0086418,
umls-concept:C0201734,
umls-concept:C0521115,
umls-concept:C1122087
|
pubmed:issue |
6
|
pubmed:dateCreated |
2003-7-15
|
pubmed:abstractText |
Because traditional therapies for rheumatoid arthritis (RA) such as methotrexate (MTX) do not produce an adequate response in many patients, newer therapies that block the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) are increasingly being used in combination with MTX.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0149-2918
|
pubmed:author |
pubmed-author:ChartashElliot KEK,
pubmed-author:FischkoffSteven ASA,
pubmed-author:FurstDaniel EDE,
pubmed-author:GrannemanG RichardGR,
pubmed-author:KeystoneEdward CEC,
pubmed-author:MorelandLarry WLW,
pubmed-author:NoertersheuserPeter APA,
pubmed-author:PaulusHarold EHE,
pubmed-author:TeohLeah SLS,
pubmed-author:VelagapudiRaja BRB,
pubmed-author:WeinblattMichael EME,
pubmed-author:WeismanMichael HMH
|
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1700-21
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12860493-Adult,
pubmed-meshheading:12860493-Aged,
pubmed-meshheading:12860493-Antibodies, Monoclonal,
pubmed-meshheading:12860493-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:12860493-Antirheumatic Agents,
pubmed-meshheading:12860493-Area Under Curve,
pubmed-meshheading:12860493-Arthritis, Rheumatoid,
pubmed-meshheading:12860493-Dose-Response Relationship, Drug,
pubmed-meshheading:12860493-Double-Blind Method,
pubmed-meshheading:12860493-Drug Therapy, Combination,
pubmed-meshheading:12860493-Female,
pubmed-meshheading:12860493-Half-Life,
pubmed-meshheading:12860493-Humans,
pubmed-meshheading:12860493-Injections, Intravenous,
pubmed-meshheading:12860493-Injections, Subcutaneous,
pubmed-meshheading:12860493-Male,
pubmed-meshheading:12860493-Methotrexate,
pubmed-meshheading:12860493-Middle Aged,
pubmed-meshheading:12860493-Pilot Projects,
pubmed-meshheading:12860493-Treatment Outcome,
pubmed-meshheading:12860493-Tumor Necrosis Factor-alpha
|
pubmed:year |
2003
|
pubmed:articleTitle |
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
|
pubmed:affiliation |
Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. weisman@cshs.org
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|